Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques rather than neuronal damage.

Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB ...

Johns Hopkins researchers found that bats adapt to hearing loss using innate neural strategies, such as increasing ...

New research suggests previous assumptions about the pathogenesis of spinal muscular atrophy (SMA) are inadequate.

A potential new treatment for Alzheimer’s disease may come in the form of a nasal spray. Researchers in Italy have discovered ...

APOE4 carriers had higher blood-brain barrier permeability, even without cognitive decline or amyloid beta buildup, ...

Researchers have identified that G-quadruplexes promote harmful protein aggregation in neurodegenerative diseases. Blocking ...

A new study indicates that the loss of brain volume associated with the Alzheimer's drug lecanemab shows the drug is working ...

ATHENS—Ohio University College of Arts and Sciences Professor Dr. Mitchell Day has been awarded a significant grant of $453,000 from the National Institutes of Health (NIH) to explore the ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

Activating certain neurons during fertile phases set off rejection behavior, while silencing them in non-receptive females ...

Men with cardiovascular disease risk factors, including obesity, face brain health decline a decade earlier—from their mid ...